Review of Liver Enzymes Abnormalities in Patients with SARS-CoV-2 Infection
Waseem F. Al Tameemi,
Anas Habeeb Mohammed Matar Al-Sharqi
Issue:
Volume 10, Issue 1, January 2022
Pages:
1-7
Received:
10 November 2021
Accepted:
30 November 2021
Published:
8 January 2022
Abstract: Background: Liver function derangements have been reported in COVID-19, but reported rates are variable. Treatment in intensive care units (ICU) has become a major challenge; therefore, early recognition of severe and critical cases is absolutely essential for timely triaging of patients. Objectives: to review incidence of acute liver injury in patients with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). Patients and methods: obtaining clinical records and laboratory results prospectively from one hundred patients with PCR-confirmed or radiography-confirmed COVID-19, who are admitted to the isolation wards and emergency departments of three different hospitals in Baghdad from 1st of December 2020 to 31st of March 2021. Results: The mean age group of study sample was (61.2±12.36) years, males formed 59%. GI manifestations were recorded in 47% of total cases, and were statistically correlated with disease severity (P value 0.001). Wide range of LFT abnormalities are found in patients with COVID-19, but none of which showed statistical significance in relation to disease severity. When LFT results were reviewed in relation to previous comorbidities, GGT was found to be statistically correlated with the underlying CLD (P value 0.001), and ALP with both underlying CLD and DM (P values <0.001 and 0.029, respectively) and even in the absence of underlying comorbidity (P value 0.006). Conclusion: Liver enzyme derangements are increasingly reported in patients with COVID-19, but are not necessarily correlate with disease severity. Cholestatic picture of liver enzyme derangement is a more commonly recorded manifestation.
Abstract: Background: Liver function derangements have been reported in COVID-19, but reported rates are variable. Treatment in intensive care units (ICU) has become a major challenge; therefore, early recognition of severe and critical cases is absolutely essential for timely triaging of patients. Objectives: to review incidence of acute liver injury in pat...
Show More
Blood Count Under the Effect of Erythropoietin (EPO) in Patients with Chronic Hemodialysis
Elvedin Osmanovic,
Mersiha Cerkezovic,
Almir Jagodic
Issue:
Volume 10, Issue 1, January 2022
Pages:
8-12
Received:
18 December 2021
Accepted:
5 January 2022
Published:
12 January 2022
Abstract: One of the most common associated diseases in dialysis patients is anemia. The number of erythrocytes, hemoglobin and hematocrit is reduced in patients that suffer from anemia. These three measurement parameters represent the most important "red part" of the blood count. Due to renal insufficiency, patients on hemodialysis do not have enough erythropoietin, which healthy kidneys excreted, and is necessary for hematopoiesis. Erythropoietin (EPO) is the main regulator of the daily production of red blood cells. EPO that is execrated by peritubular capillary membrane cells in the kidneys circulates within plasma in order to interact with target cells in the bone marrow to maintain or stimulate erythropoiesis. The main purpose of the action of EPO is the formation of erythroid colonies. During observation of differences in the ordination of EPO in each group between men and women, there is no statistical significance evident in the incidence of anemia before and after therapy, as in p=0.70. The target concentration of hemoglobin, which must be constantly maintained in people with chronic renal anemia, is 110-120 g/l, while the target value of the number of red blood cells is 4-5x1012/l and the hematocrit value is 0.35-4.5 l/l, with a slight outflow depending on the gender of the patient. The final values of the participants in our study treated with epoetin alpha show higher values of hemoglobin, hematocrit and erythrocytes, while the average values recorded in participants treated with darbepoetin decreased.
Abstract: One of the most common associated diseases in dialysis patients is anemia. The number of erythrocytes, hemoglobin and hematocrit is reduced in patients that suffer from anemia. These three measurement parameters represent the most important "red part" of the blood count. Due to renal insufficiency, patients on hemodialysis do not have enough erythr...
Show More
Neuroleptic Therapy as an Antitumor Protective Factor in Schizophrenic Patients with Polysindromic Framework: Observational Study
Leopoldo Ferrante,
Walter Filippelli,
Luigi Petrillo,
Giovanni Castaldo,
Alessio Sullo,
Gaetano Motta,
Anna D’Alessio
Issue:
Volume 10, Issue 1, January 2022
Pages:
13-19
Received:
19 January 2021
Accepted:
2 February 2021
Published:
28 January 2022
Abstract: Schizophrenia is one of the psychiatric pathologies that involves the highest family, social and economic costs. The symptomatology affects various areas of an individual's life that include thought, emotions and the social aspect, with a remarkably long and variable course of the pathology, with subjects who may be chronically ill and others, instead, subjected to exacerbations and remissions. Despite the high efforts and advances in the field of pharmacology and psychotherapy treatments, to date, a real 'restitutio ad integrum' has not yet been reached. The drug therapy par excellence used to restore the biochemical balance is given by typical and atypical neuroleptics. The use of these drugs has led to widespread debates on the relationship between schizophrenia and cancer, as they appear to have an anti-tumor protective factor. In the Villa dei Pini Neuripsychiatric facility in Avellino, in a period between 2006 and 2016, an observational study was carried out on a population of patients diagnosed with schizophrenia (DSM-IV. TR). Each hospitalized subject, both new admission and re-entry, underwent clinical interview and a complete blood count with a chest x-ray. 4962 records of patients with Schizophrenic Psychosis have been taken into consideration, belonging to 888 patients (660 M and 228F) who had a history of being heavy smokers (about 90%) with concomitant depressive symptomatology (about 70%), hypertension (65%) and hearing loss (55%); the patients have been re-evaluated over time: at each re-entry into the clinic a complete blood count was performed with leukocyte formula, VES and PCR, and a Thoracic X-ray (the average number of patients returned to the clinic and 6 for patients 4 for female patients); some others were contacted by telephone interview. All the patients taken into consideration had at least one neuroleptic drug in therapy during the hospital stay. Among these patients, re-evaluated over time at each re-entry into the clinic or reached by telephone interview, about 2% (16 patients) developed lung K; the incidence is greater in patients with more than one comorbidity (diabetes, hypertension with familiarity due to oncological pathology). The data collected seem to go in the direction of the observations made by the various authors over time, that is the role of neuroleptic drugs as a protective factor in the onset and development of cancer, especially in the lung. To date the schizophrenia and cancer controversy is still open and in a phase of strong interest.
Abstract: Schizophrenia is one of the psychiatric pathologies that involves the highest family, social and economic costs. The symptomatology affects various areas of an individual's life that include thought, emotions and the social aspect, with a remarkably long and variable course of the pathology, with subjects who may be chronically ill and others, inst...
Show More
